Asthma

ACCP Asthma

ACCP GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/60221

Contents of this Issue

Navigation

Page 8 of 11

Table 6. Quick Relief Medications Dosage Form Generic ( ) Short-acting β2 Albuterol (ProAir HFA® Proventil HFA® Ventolin HFA® , , ) Pirbuterol (Maxair® 200 mcg/dose ) Levalbuterol (Xopenex HFA® Albuterol (Proventil® Albuterol (Ventolin Nebules® ) Levalbuterol (Xopenex® ) MDI Ipratropium (Atrovent HFA® Albuterol/ ipratropium MDI (Combivent® ) 45 mcg/dose ) Nebulizer solution† ) 1 mg/mL (0.83% in 3 mL) 2.5 mg/3 mL (0.083% in 3 mL, 0.5% in 20 mL) 0.31, 0.63, 1.25 mg per 3 mL 17 mcg/dose ) Combinations (Use for acute bronchospasm. Some synergism with both agents. Primary indication is COPD.) ) Nebulizer Sol (Duoneb® 103 mcg albuterol/18 mcg ipratropium per dose 2.5 mg albuterol (0.083% in 3 mL) 0.5 mg ipratropium (0.017% in 3 mL) 2 inh qid prn Max dose: 12 inh/d 5 min 3-4 h 2.5 mg q6-8h prn 1.25-5 mg q6-8h prn 0.63-1.25 mg q6-8h prn Anticholinergics (Use for acute bronchospasm in patients with β2 of choice for beta blocker-induced asthma.) 2 inh qid Max dose: 12 inh/d 5 min 10-15 min 10-17 min 3-4 h 4-6 h 5-8 h -agonist intolerance. Therapy 15 min 2-4 h -agonists (Use for relief of acute symptoms and prevention of exercise-induced bronchospasm.) MDI 90 mcg/dose 2 inh q4-6h prn; in some patients, 1 inh q4h may be sufficient 2 inh 15 min before exercise 2 inh q4-6h prn, in some patients, 1 inh q4h may be sufficient Max dose: 12 inh/q24h 2 inh q4-6h prn, in some patients, 1 inh q4h may be sufficient ≤ 15 min 3-6 h Dose* Onset Duration < 5 min 5 h 5-10 min 3-4 h ≥ 18 years old 3 mL q4-6h prn; Max dose: 18 mL/24 h 5 min 3-4 h *See product labeling for complete prescribing information. • Nebulizer medications are not therapy of choice for patients at home, but may be indicated under certain circumstances. • For more information on FDA changes to MDIs containing CFC's please see http://www.fda.gov/cder/mdi/consumer.htm and http://www.fda.gov/CDER/mdi/mdifaqs.htm. 7 Br and

Articles in this issue

Links on this page

Archives of this issue

view archives of Asthma - ACCP Asthma